Before prescribing these medications, healthcare providers consider BMI, medical history, existing health conditions, and current medications
Weight loss occurred progressively during the first 60 weeks, and was maintained for the rest of the trial
Speak with your prescribing physician to help determine whether symptoms are a temporary adaptation or a sign that adjustments are needed
In conclusion, BARI-STEP, a randomized, placebo-controlled trial investigating the use of once-weekly semaglutide 2.4 mg in a post-bariatric patient population with a suboptimal clinical response, demonstrates that semaglutide 2.4 mg in patients with a suboptimal clinical response results in substantial, clinically relevant body weight reduction, and improvements in metabolic health and quality of life
Ozempic: The clinical trials Both Mounjaro and Ozempic/Wegovy have been extensively studied in clinical trials for both safety and effectiveness, including in the long term